CHLORZOXAZONE Drug Interactions
Also known as: CHLORZOXAZONE
Chlorzoxazone is a medication used to help relieve discomfort from sudden, painful muscle and bone conditions. It works by affecting the central nervous system, which helps reduce pain and muscle spasms, often alongside rest and physical therapy.CHLORZOXAZONE has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Patients may experience increased sedation, dizziness, and psychomotor impairment. The most serious clinical effect is an enhanced risk of respiratory depression, which can be life-threatening. Other effects include profound somnolence, confusion, and difficulty concentrating.
Mechanism
Buprenorphine, an opioid partial agonist, exerts its primary effects through mu-opioid receptor agonism, leading to central nervous system (CNS) depression. Chlorzoxazone, a centrally acting muscle relaxant, also causes CNS depression by acting on subcortical and spinal cord levels. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of buprenorphine and chlorzoxazone if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate carefully, monitoring closely for signs of CNS and respiratory depression. Educate patients about the risks and advise them to avoid driving or operating heavy machinery.
Concomitant use can result in profound sedation, respiratory depression, hypotension, and psychomotor impairment. Patients may experience dizziness, confusion, and difficulty with coordination, increasing the risk of falls and accidents. In severe cases, this interaction can lead to respiratory arrest and death.
Mechanism
Fentanyl, an opioid analgesic, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Chlorzoxazone, a centrally acting skeletal muscle relaxant, also exerts its effects through CNS depression, likely by inhibiting polysynaptic reflexes at the spinal cord and subcortical levels. The co-administration of these agents leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of fentanyl and chlorzoxazone if possible. If co-administration is necessary, initiate both medications at lower doses and titrate carefully while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against operating heavy machinery or driving. Consider alternative non-opioid analgesics or non-pharmacological muscle relaxants.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Hypotension and syncope are also possible.
Mechanism
Oxycodone is an opioid agonist that primarily acts on mu-opioid receptors in the central nervous system (CNS), leading to analgesia, sedation, and respiratory depression. Chlorzoxazone is a centrally acting muscle relaxant that inhibits polysynaptic reflex arcs in the spinal cord and subcortical areas, also causing CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxycodone and chlorzoxazone if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate carefully while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, and impaired psychomotor function, increasing the risk of falls and accidents. There is a significant risk of respiratory depression, which can be life-threatening, particularly in opioid-naive individuals or those with underlying respiratory compromise. Cognitive impairment and decreased level of consciousness are also common.
Mechanism
Morphine, an opioid analgesic, exerts its effects primarily through mu-opioid receptor agonism in the central nervous system (CNS), leading to dose-dependent CNS depression. Chlorzoxazone, a centrally acting muscle relaxant, also causes generalized CNS depression, though its precise mechanism is not fully elucidated but involves inhibition of polysynaptic reflexes. The concomitant use of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should be avoided if possible. If unavoidable, initiate both medications at the lowest effective doses and titrate cautiously, closely monitoring for signs of CNS and respiratory depression. Educate patients on the risks and advise against operating heavy machinery or driving. Consider alternative non-opioid pain management or non-benzodiazepine muscle relaxants if appropriate.
Patients may experience increased drowsiness, dizziness, confusion, and psychomotor impairment. There is a significant risk of respiratory depression, which can be life-threatening, and profound sedation that may impair the ability to operate machinery or perform other hazardous tasks.
Mechanism
Both tramadol, an opioid analgesic, and chlorzoxazone, a centrally acting muscle relaxant, produce central nervous system (CNS) depression. The co-administration of these agents results in an additive depressant effect on the CNS, leading to enhanced sedation and respiratory depression.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, initiate with the lowest effective doses of both medications and monitor patients closely for signs of CNS and respiratory depression. Educate patients about the risks and advise against driving or operating heavy machinery.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Other effects include profound drowsiness, decreased cognitive function, and impaired coordination.
Mechanism
Codeine sulfate, an opioid analgesic, exerts its effects primarily through agonism of mu-opioid receptors in the central nervous system (CNS), leading to CNS depression. Chlorzoxazone, a centrally acting skeletal muscle relaxant, also produces CNS depression by inhibiting multisynaptic reflex arcs in the spinal cord and subcortical areas. The co-administration of these agents results in additive CNS depressant effects.
Clinical Management
Avoid concomitant use of codeine sulfate and chlorzoxazone if possible. If co-administration is necessary, initiate therapy with the lowest effective doses of both drugs and titrate carefully while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks of additive sedation and advise against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, and confusion. There is an increased risk of respiratory depression, which can be life-threatening, and psychomotor impairment, leading to an elevated risk of falls and accidents. Other effects include hypotension and decreased level of consciousness.
Mechanism
Both methadone, an opioid analgesic, and chlorzoxazone, a centrally acting skeletal muscle relaxant, exert depressant effects on the central nervous system (CNS). The co-administration of these agents leads to an additive pharmacological effect, increasing the overall CNS depression. This synergistic action can significantly impair neuronal activity in various brain regions.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe CNS and respiratory depression. If co-administration is unavoidable, reduce the starting dose of one or both drugs, monitor patients closely for signs of sedation and respiratory depression, and educate them on the risks. Naloxone should be readily available for opioid overdose reversal.
Patients may experience profound sedation, dizziness, impaired psychomotor function, and increased risk of falls. The most serious clinical effect is respiratory depression, which can be life-threatening. Other effects include hypotension and coma.
Mechanism
Hydromorphone, an opioid analgesic, acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia, sedation, and respiratory depression. Chlorzoxazone, a centrally acting muscle relaxant, also exerts its effects within the CNS, primarily by inhibiting polysynaptic reflex arcs. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, initiate both drugs at the lowest effective doses and titrate carefully, monitoring closely for signs of CNS and respiratory depression. Educate patients about the risks and advise against operating machinery or driving.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an enhanced risk of respiratory depression, which can be life-threatening. Other effects include profound sedation and impaired motor function.
Mechanism
Oxymorphone is an opioid agonist that produces central nervous system (CNS) depression by binding to mu-opioid receptors. Chlorzoxazone is a centrally acting skeletal muscle relaxant that also causes generalized CNS depression. The concurrent use of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxymorphone and chlorzoxazone if possible. If co-administration is necessary, use the lowest effective doses for the shortest duration possible, and monitor patients closely for signs of respiratory depression, sedation, and mental status changes. Educate patients and caregivers about the risks and symptoms of CNS depression.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. There is an elevated risk of respiratory depression, which can be life-threatening, and profound hypotension.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist and norepinephrine reuptake inhibition properties, leading to central nervous system (CNS) depression. Chlorzoxazone is a centrally acting muscle relaxant that also causes CNS depression. The concomitant use of these agents results in additive CNS depressant effects.
Clinical Management
Concomitant use should generally be avoided. If co-administration is necessary, initiate both drugs at the lowest effective doses and titrate carefully while closely monitoring for signs of CNS depression, respiratory depression, and hypotension. Advise patients to avoid driving or operating heavy machinery and to avoid other CNS depressants, including alcohol.
For complete prescribing information:
View full CHLORZOXAZONE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.